GlassScriptPhysician profile
Vishnu Kalidindi
NPI 1487611273
$3,018.19
in general payments reported to CMS, 2019-2025
24 companies · $557 in 2025
The $557 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $152 · 2021: $265 · 2022: $480 · 2023: $669 · 2024: $722 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $555.19 | 2019-2025 | |
| Novo Nordisk INC | $551.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $337.18 | 2021-2025 | Verquvo |
| Heartflow, INC. | $230.72 | 2020-2024 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.12 | 2019-2025 | Jardiance |
| Pfizer INC. | $162.54 | 2022-2025 | |
| Amgen INC. | $150.15 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $129.94 | 2022-2025 | Camzyos |
| Biotronik INC. | $102.03 | 2024 | Orsiro Mission |
| Astrazeneca Pharmaceuticals LP | $95.64 | 2020-2025 | Farxiga |
| Chiesi USA, INC. | $73.16 | 2021-2024 | Kengreal, Cleviprex |
| Janssen Pharmaceuticals, INC | $51.18 | 2022-2024 | Xarelto |
| Abiomed | $34.64 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.76 | 2023-2024 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $29.94 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Inspire Medical Systems, INC. | $24.85 | 2025 | Inspire |
| Abbott Laboratories | $24.24 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $24.05 | 2024 | Arcalyst |
| Cleerly, INC. | $20.57 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals, LTD. | $19.95 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $18.81 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.89 | 2024 | |
| Medtronic Vascular, INC. | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishnu Kalidindi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.